Experimental immune cell therapy targets hidden leukemia
NCT ID NCT05535855
First seen Nov 15, 2025 · Last updated Apr 21, 2026 · Updated 24 times
Summary
This early-stage trial is testing the safety of a personalized immune cell therapy called CAR T-cells in adults with B-cell acute lymphoblastic leukemia (B-ALL). The study is for patients who have achieved their first remission but still have tiny, undetectable amounts of cancer cells left in their body. Researchers will give patients modified immune cells designed to hunt and destroy these remaining leukemia cells to try to prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.